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confidence interval around the estimate for bleeding was
near to 1. When a cohort of 1,000 simulated patients
with DVT received secondary prophylaxis with LMWH
instead of warfarin 4.5 lives were saved, i.e. 22 addi-
tional days of life and 18 additional quality-adjusted
days. Prophylaxis with LMWH cost $768 more than
prophylaxis with warfarin, which is $15,360 per QALY
saved. The results were sensible to the efficacy of LMWH
in reducing pulmonary embolism: LMWH is no longer
effective if patients incur 35% more episodes of pulmo-
nary embolism than with warfarin. CONCLUSIONS:
LMWH is a cost-effective drug to perform secondary
prophylaxis after a thromboembolic episode. However,
some critical issues need to be definitively ascertained be-
fore recommending it: first, the neat preventive efficacy
of LMWH over warfarin need to be assessed by larger
trials; second, patient preferences for oral or subcutane-
ous administrations are to be elicited.
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OBJECTIVE: To study the patterns of prescribing of abcix-
imab, a platelet function inhibitor, in percutaneous translu-
minal coronary angioplasty (PTCA) centres and to identify
which factors determine the level of usage per centre.
METHODS: The opinion-leading cardiologists from all 13
PTCA centres in the Netherlands have co-operated in our
research. The questions about the use of abciximab in 1998
concerned indications, number of PTCAs performed, num-
ber of patients treated with abciximab, the funding and
possible financial restrictions on the treatment, participa-
tion in clinical trials in the past, the proportion of patients
receiving stents, and opinion on the appropriate level of ab-
ciximab usage. RESULTS: The level of abciximab usage
varies markedly between centres, ranging from 2% to 36%
of all PTCA procedures. Three out of four abciximab pre-
scriptions surround stenting procedures. The indications
for prescribing abciximab significantly differed between
centres. Many physicians use abciximab not only to pre-
vent thrombotic complications, but also to treat acute com-
plications when they occur during PTCA and in case of
suboptimal results. Together: budget, investigatorship, size,
and type of the institution are highly predictive for the level
of abciximab usage (R2  0.96, P  0.001). The more pa-
tients doctors have included in clinical trials in the past, the
higher the likelihood they prescribe abciximab. CONCLU-
SIONS: Shortly after its introduction, patterns of abcix-
imab prescribing varied significantly between PTCA cen-
tres. Abciximab is not only administered preventively, but
also during and after the procedure, even though this strat-
egy has never been evaluated in controlled trials. Budget
and involvement in clinical trials in the past were important
predictors of the level of usage in each centre. This is not a
desirable situation, since it indicates that the level of pre-
scribing is not so much based on patient mix, but is largely
explained by non-medical factors.
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OBJECTIVE: Given that secondary prevention of athero-
thrombotic disease with antiplatelets drugs is widely es-
tablished in our country, in the present paper an attempt
is made to compare the cost and effectiveness of 325 mg
aspirin versus 75 mg clopidogrel once daily. METHODS:
A decision analysis model was developed based on epide-
miological and clinical data, the effectiveness ratios, the
health care resource utilization and unit cost. It was as-
sumed that the effects of clopidogrel in Greek patients
would be the same as those of the CAPRIE study (1996).
Direct and indirect cost was estimated. Patients hospital-
ized for ischaemic, cerebrovascular and peripheral artery
disease were selected for evaluation. Clinical, demographic
and economic data derive from the National Statistical
Office of Greece and the Ministry of Labour and Social
Security. Effectiveness is expressed in years of life saved
and all results are calculated on 1 year of treatment. RE-
SULTS: Total cost for patients suffering from athero-
thrombotic disease in 1998 in Greece, is estimated at
$1,05 billion, while 44.5% concerns the indirect cost.
The incremental cost per year of life saved is $16,717 per
patient suffering from ischaemic and peripheral disease
(moderate events) and $3,217 per severe event. Addition-
ally, the incremental cost per year of life saved for patients
with cerebrovascular disease is estimated at $13,717 per
moderate event and $1,550 per severe event without dis-
counting. The administration of clopidogrel compared
with aspirin yields an annual gain of 257 years of life to
working force patients and a net annual societal benefit
that ranges from $6 to $10 million. Sensitivity analysis
showed that outcomes are sensitive to price differences
between the two drugs and the severity of illness.
CONCLUSION: Our analysis showed that clopidogrel
treatment is cost-effective, especially in severe events.
Economic evaluation results should be incorporated in
the decision-making of the health care sector in Greece.
